IDEX Corp
IEX
232.91
-3.37
-1.43%
IDEX Corp
US · IEX
#1045 by market cap
Listed 1970
232.91
-3.37
-1.43%
Live - 5344 symbols - heartbeat 527s ago
· 2026-10-08 07:39
Pre-market
230.73
-0.94%
After-hours
232.91
0.00%
- Market cap
- 17.17B
- P/E (TTM)i
- 33.51
- P/Bi
- 4.28
- EPSi
- 6.41
- Div yieldi
- 1.54%
- 52W posi
- 88%
Reader sentiment
Are you bullish or bearish on IEX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.4 percentage points.
Institutional ownership
- Held by institutions
- 104.57% +0.37pp
- Institutions
- 841 -5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund83.39%
Hedge Fund12.45%
Public Company2.65%
Government Pension Fund1.82%
Private Company1.72%
Sovereign Wealth Fund1.30%
Corporate Pension Plan0.60%
Family Office/Trust0.25%
Insurance Company0.25%
Top holders as of 2026-06-30
BlackRock
7.78% · 5.73M sh
Vanguard Capital Management, LLC
7.13% · 5.26M sh
Vanguard Portfolio Management, LLC
5.07% · 3.73M sh
State Street Global Advisors
4.50% · 3.32M sh
PRIMECAP Management Company
4.48% · 3.30M sh
Millennium Management LLC
3.21% · 2.37M sh
Eaton Vance Management
3.13% · 2.30M sh
Geode Capital Management, LLC
2.85% · 2.10M sh
Nordea Investment Management AB
2.50% · 1.84M sh
UBS Asset Management
2.16% · 1.59M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 33 buys · 10 sells
| Name | Role | Stake |
|---|---|---|
| Eric Ashleman | Chief Executive Officer | 0.08% |
| David Parry | Independent Director | 0.03% |
| Sean Gillen | Senior Vice President | 0.03% |
| Katrina Helmkamp | Independent Non-Executive Chairperson | 0.01% |
| Abhishek Khandelwal | Senior Vice President | 0.01% |
| Tara Tereso | Group Executive of Health & Science Technologies | 0.01% |
| Akhil Mahendra | Interim CFO & VP of Corporate Development | 0.01% |
| Livingston Satterthwaite | Independent Director | 0.01% |
| Lisa Anderson | Senior Vice President | 0.01% |
| Allison Lausas | Chief Accounting Officer & Interim CFO | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-15 | Tara Tereso | Group Executive of Health & Science Technologies | Sale to Issuer | -290 | $222.84 |
| 2026-09-15 | William Simmons | -- | Sale to Issuer | -218 | $222.84 |
| 2026-09-10 | Tara Tereso | Group Executive of Health & Science Technologies | Sale to Issuer | -138 | $221.46 |
| 2026-08-28 | Allison Lausas | Chief Accounting Officer & Interim CFO | Sale to Issuer | -645 | $230.28 |
| 2026-08-11 | Lisa Anderson | Senior Vice President | Derivative Exercise and Sale | -385 | $93.27–238.59 |
| 2026-05-10 | Eric Ashleman | Chief Executive Officer | Derivative Exercise and Sale | -15,385 | $93.27–215.81 |
| 2026-05-05 | Carl Christenson | Independent Director | Other Acquisition | +805 | -- |
| 2026-05-05 | Mark Buthman | Independent Director | Other Acquisition | +805 | -- |
| 2026-05-05 | Katrina Helmkamp | Independent Non-Executive Chairperson | Other Acquisition | +1,035 | -- |
| 2026-05-05 | Matthijs Glastra | Director | Other Acquisition | +805 | -- |
| 2026-05-05 | Mark Beck | Independent Director | Other Acquisition | +805 | -- |
| 2026-05-05 | Stephanie Disher | Director | Other Acquisition | +805 | -- |
| 2026-05-05 | Alejandro Quiroz Centeno | Independent Director | Other Acquisition | +805 | -- |
| 2026-05-05 | Lakecia Gunter | Independent Director | Other Acquisition | +805 | -- |
| 2026-05-05 | L. Watts-Stanfield | Independent Director | Other Acquisition | +805 | -- |
| 2026-03-03 | Roopa Unnikrishnan | Senior Vice President of Strategy & Corporate Development | Intent to Sell (Form 144) | -4,309 | $204.41 |
| 2026-02-22 | Tara Tereso | Group Executive of Health & Science Technologies | Sale to Issuer | -154 | $207.48 |
| 2026-02-21 | Eric Ashleman | Chief Executive Officer | Other Acquisition | +9,040 | -- |
| 2026-02-21 | Eric Ashleman | Chief Executive Officer | Other Derivative Acquisition | +38,165 | $207.48 |
| 2026-02-19 | Allison Lausas | Chief Accounting Officer & Interim CFO | Sale to Issuer | -179 | $207.86 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:39:34 · For reference only, not investment advice and not tailored to your situation.